Related Experiment Video

Updated: Jul 1, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumocystis pneumonia in non-HIV immunocompromised patients in 2026: evolving therapeutic standards

Hélène Kemp1, Virginie Lemiale1, Elie Azoulay1

  • 1Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Saint Louis, Université Paris-Cité, Paris, France.

Expert Review of Anti-Infective Therapy
|June 29, 2026
PubMed

Insights

Pneumocystis jirovecii pneumonia (PJP) is a severe lung infection in immunocompromised individuals. Early suspicion and prompt treatment are crucial for better outcomes, especially in non-HIV patients.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Immunology

Background:

  • Pneumocystis jirovecii pneumonia (PJP) is a life-threatening infection.
  • It primarily affects individuals with impaired T-cell immunity.
  • PJP incidence and severity are increasing in non-HIV patients.

Purpose of the Study:

  • To discuss the mechanism of PJP.
  • To review clinical presentation and imaging findings.
  • To emphasize prompt treatment initiation and management strategies.

Main Methods:

  • Literature review on PJP mechanisms, host response, and clinical aspects.
  • Discussion of diagnostic and therapeutic options.
  • Analysis of current research and future directions.

Main Results:

  • PJP presents a severe disease course and poorer outcomes in non-HIV patients compared to HIV patients.
  • Prompt treatment initiation, even before diagnostic confirmation, is vital.
  • A comprehensive overview of prophylactic and therapeutic agents, including adverse events, is provided.

Conclusions:

  • High clinical suspicion for PJP in immunocompromised patients with acute respiratory failure is essential.
  • Future research should focus on individualized risk prediction, standardized diagnostic criteria (e.g., quantitative PCR thresholds), and optimized treatment strategies for PJP in non-HIV populations.
Abstract

Keywords:
HIV-negative patientsPneumocystis jiroveciiimmunocompromised patientsprophylaxistreatment

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: